Day: April 23, 2021

MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), uma empresa farmacêutica especializada panamericana (ex-EUA), anunciou hoje que celebrou um acordo definitivo pelo qual a Knight adquirirá os direitos exclusivos para fabricar, comercializar e vender Exelon® (adesivo de rivastigmina, cápsulas e solução) no Canadá e na América Latina (o “Território”), assim como uma licença exclusiva para usar a propriedade intelectual e a marca Exelon da Novartis dentro do Território. Exelon (rivastigmina) é um produto de prescrição que foi aprovado pela primeira vez em 1997 e atualmente está registrado e é vendido em aproximadamente 90 países. O Exelon é indicado para o tratamento sintomático da demência leve a moderadamente grave em pessoas com doença de Alzheimer. No fechamento...

MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) una compañía farmacéutica especializada panamericana (ex-EE.UU.), anunció hoy que ha celebrado un acuerdo definitivo en virtud del cual Knight adquirirá el derechos exclusivos para fabricar, comercializar y vender Exelon® (parche de rivastigmina, cápsulas y solución) en Canadá y América Latina (el “Territorio”), así como una licencia exclusiva para usar la propiedad intelectual y la marca comercial Exelon de Novartis dentro del Territorio. Exelon (rivastigmina) es un producto recetado que se aprobó por primera vez en 1997 y actualmente está registrado y es vendido en aproximadamente 90 países. Exelon está indicado para el tratamiento sintomático de la demencia leve a moderadamente grave en personas con la enfermedad...

MONTRÉAL, 23 avr. 2021 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société »), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd’hui la conclusion d’une entente définitive par laquelle Knight acquerra les droits exclusifs de fabrication, de commercialisation et de vente d’Exelon® (timbre, capsules et solution de rivastigmine) au Canada et en Amérique latine (le « territoire »), ainsi qu’une licence exclusive d’utilisation de la propriété intellectuelle et de la marque Exelon, de Novartis dans le territoire. Exelon (rivastigmine) est un produit délivré sur ordonnance approuvé pour la première fois en 1997 et présentement homologué et vendu dans quelque 90 pays. Exelon est indiqué pour le traitement symptomatique de la démence légère à modérément sévère parmi les patients...

Not for release to US wire services or distribution in the United States TORONTO, April 23, 2021 (GLOBE NEWSWIRE) — Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce the Company has received firm commitments for a placement to eligible professional and sophisticated investors of approximately 163.8 million fully-paid ordinary shares in Xanadu (New Shares) at an issue price of $0.062 each to raise approximately $10.2 million (before costs) (Placement). HighlightsFirm commitments received for a Placement to raise approximately $10.2 million (before costs) Well supported by both domestic and international institutions Strong financial position to deliver Kharmagtai exploration strategy, targeting resource growth and definition of high-grade bornite-rich zones at depth Concurrent with the Placement,...

The meeting of the Supervisory Board of AB Kauno Energija has been held on April 21, 2021. The decision in accordance with Items 1 and 6 of Paragraph 1 of Article 32 of the Law on Companies of the Republic of Lithuania has been made, as follows:1) to accept and propose to the General Meeting of Shareholders of AB Kauno Energija to approve the audited Consolidated Financial Statements of AB Kauno Energija for the year 2020 prepared in accordance with International Financial Reporting Standards as adopted by the European Union, together with a Consolidated Annual Report and an independent auditor’s conclusion;2) to accept and propose to the General Meeting of Shareholders of AB Kauno Energija to allocate the profit of AB Kauno Energija in accordance with the 2020 year profit (loss) allocation project submitted to the General Meeting of...

AB „Kauno energija“ stebėtojų taryba 2021 m. balandžio 21 d. posėdyje, vadovaudamasi Lietuvos Respublikos akcinių bendrovių įstatymo 32 straipsnio 1 dalies 1 ir 6 punktais, nusprendė:pritarti ir siūlyti AB „Kauno energija“ eiliniam visuotiniam akcininkų susirinkimui tvirtinti audituotą AB „Kauno energija“ konsoliduotųjų ir Bendrovės 2020 m. finansinių ataskaitų rinkinį, parengtą pagal Tarptautinius finansinės atskaitomybės standartus, priimtus taikyti Europos Sąjungoje, pateiktą kartu su konsoliduotuoju metiniu pranešimu bei nepriklausomo autoriaus išvada; pritarti ir siūlyti AB „Kauno energija“ eiliniam visuotiniam akcininkų susirinkimui paskirstyti AB „Kauno energija“ pelną pagal eiliniam visuotiniam akcininkų susirinkimui pateiktą 2020 m. pelno (nuostolių) paskirstymo projektą; pritarti AB „Kauno energija“ veiklos strategijos įgyvendinimui...

EDMONTON, Alberta, April 23, 2021 (GLOBE NEWSWIRE) — Visionstate Corp. (TSX-V: VIS) (“Visionstate” or ‘the Company”) is pleased to announce that on April 15, 2021, it has signed a Letter of Intent to acquire the outstanding shares of Exceed Solar, an Alberta-based renewable energy company focused on smart, high-tech building envelopes for residential applications. The strategic acquisition is in line with Visionstate’s mission of advancing sustainability and represents a business opportunity for both companies as they explore synergies between their technologies. Visionstate Corp. will acquire the outstanding shares of Exceed Solar for $100,000 cash and $200,000 in Visionstate Corp. shares at $0.10 for a total consideration of $300,000. Visionstate currently owns 40% of Exceed Solar through a convertible debenture of $200,000 signed...

Kapitalforeningen BLS Invest afholdte den 20. april 2021 ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2020 herunder de tidligere udbetalte foreløbige udlodninger samt bestyrelsens honorar for 2020 blev godkendt af generalforsamlingen. På generalforsamlingen var der stillet forslag til ændring af vedtægter, hvorefter afdelingerne fik mulighed for at optage kortfristede lån på højst 10 pct. af afdelingens formue, bortset fra lån med investeringsformål (gearing). Med ændringen udvides afdelingernes adgang til låneoptagelse, da lånet ikke længere skal være formålsbestemt. Med denne ændring bringes vedtægterne i overensstemmelse med lov om finansiel virksomhed § 157 a, nr. 2. Forslaget blev vedtaget med samtlige stemmer. Til bestyrelsen genvalgtes Chris Bigler, Søren B....

HONG KONG, April 23, 2021 (GLOBE NEWSWIRE) — UCLOUDLINK GROUP INC. (“uCloudlink” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission (the “SEC”) on April 23, 2021. The annual report can be accessed on uCloudlink’s investor relations website at https://ir.ucloudlink.com. The Company will also provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and American Depositary Share holders upon request. Requests should be directed to the Company’s Investor Relations Department at ir@ucloudlink.com. About UCLOUDLINK GROUP INC. uCloudlink is the world’s...